Global Drug Discovery Technologies Market to Reach $80.2 Billion by 2026

ReportLinker

Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares. -Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, June 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Drug Discovery Technologies Industry" - https://www.reportlinker.com/p05817664/?utm_source=GNW
-Online interactive peer-to-peer collaborative bespoke updates
-Access to our digital archives and MarketGlass Research Platform
-Complimentary updates for one year

Global Drug Discovery Technologies Market to Reach $80.2 Billion by 2026

Drug discovery assists in discovering new medications by using a broad range of technologies that are used for research and the introduction of new drugs. Extensive usage of therapeutics in different diseases created the requirement in drug discovery. Several techniques like RNA and nanotechnology interference are being utilized for drug discovery, in turn generating opportunities for the manufacturers of drug discovery technology in new segments. The COVID-19 pandemic caused a temporary break in drug discovery clinical trials of many diseases because the researchers, healthcare sector, and academia concentrated on stopping the spread of coronavirus. However, the pandemic`s impact led to the invention and adoption of new working ways, which paved a path for future clinical trials. Clinical trial physicians and sponsors are highly flexible in administering virtual study and acquiring the study data remotely utilizing modern medical wearables. The new advancements are simplifying the complicated procedures and overcoming the lack of required onsite professionals. The drug discovery market is anticipated to gain an advantage by adopting technological advancements together with the biotechnology and pharmaceutical sectors. Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at US$53.3 Billion in the year 2021, is projected to reach a revised size of US$80.2 Billion by 2026, growing at a CAGR of 8.1% over the analysis period. Small Molecule Drugs, one of the segments analyzed in the report, is projected to grow at a 7.8% CAGR to reach US$60.2 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biologics segment is readjusted to a revised 8.8% CAGR for the next 7-year period. This segment currently accounts for a 23.9% share of the global Drug Discovery Technologies market.

Growth in the market is majorly driven by the growing geriatric population worldwide and people above 60 years of age are highly susceptible to chronic illnesses. The efficient drug demand from increasing affluent patients is yet another factor propelling the drug discovery global market. Furthermore, the advancements in molecular biology, biotechnology, genomics, and nanotechnology paved a path for increasing investments in drug discovery. Additionally, many blockbuster drugs` patent expiries are anticipated to make a profitable market for the existent players. Healthcare organizations worldwide are seeking drug discovery opportunities, which have been previously done using active ingredient identification from conventional remedies. It is important to discover advanced, efficient, and new drugs to fight illnesses, as there is an increase in many life-threatening illnesses and the inception of various health-related problems. The drug discovery recently has evolved significantly with technologies like NMR, mass spectrometry, chemotherapy, microplate readers, RANi, proteomics, gel electrophoresis, microfluidics, nucleic acid and protein isolation, nanotechnology, and protein and DNA microarrays. Thus, drug discovery process has become highly accurate, more refined, and less time-consuming.

Pharmaceutical organizations that are new, too, have the opportunity to launch into the drug discovery global market through generics. Pharmaceutical companies are primarily focusing on the technologies of drug development because drug discovery has a critical role to play in the cycle of drug development. However, drug development and discovery require a colossal investment and are time taking, which causes low-profit margins for pharmaceuticals. Pharmaceutical manufacturers generally face an increase in expiring patents of developed drugs, intensifying the negative impact of the research cycle`s long duration. HTS or high-throughput screening is an extensively utilized drug discovery technology, using which a huge quantity of possible biological modulators are analyzed against a defined target set. HTS technology allows biologically relevant compounds` rapid portfolio building and HTS technological advancements like multidetector readers, reliable automation, pattern and database recognition software, and imaging software and hardware are anticipated to lead the HTS technology usage. Drug discovery technologies have a huge role to play in the pharmaceutical sector`s overall growth, as the technologies immensely contribute to the innovative and blockbuster drugs` easy initiation. Diverse illnesses like CVD, cancer, and CNS disorders like Alzheimer`s and Parkinson`s generated adequate opportunities in the drug discovery technologies market.

The U.S. Market is Estimated at $16.4 Billion in 2021, While China is Forecast to Reach $12.7 Billion by 2026

The Drug Discovery Technologies market in the U.S. is estimated at US$16.4 Billion in the year 2021. The country currently accounts for a 31.12% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$12.7 Billion by the year 2026 trailing a CAGR of 10.1% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

The rise in late-stage drug failure rates is driving the demand for drug delivery technologies. The average cost of drug development has doubled in recent years to reach over US$2.6 billion. By therapeutic area, oncology and immuno-modulatory drugs are the most expensive to develop. While oncology treatment continues to dominate the existing and future drug pipelines, R&D investments on metabolic disorders, cardiovascular diseases, and respiratory diseases is gaining strength in recent years. As oncology trials require specific trial design expertise, the likelihood of attrition rates tends to be high. As new drug development is focused on the need to target many smaller subsets of indications, clinical trials are conducted on smaller patient population. A smaller market to recover R&D costs, reimbursement issues, and pushback on high drug costs further increase the average cost of drug development. Despite the scientific, technological, and operational advances in R&D aimed at increasing the efficiency and success of drug development process, a significant number of clinical trials still fail. As the early phase of clinical trials are exploratory, failure at this stage is expected to a certain extent. Failure represents the highest cost of the overall cost of drug development. Clinical trial failures may also arise when the body of knowledge about a disease or condition is limited, particularly rare diseases. Also, the rollout of more complex and extensive clinical trials is another critical factor increasing the late-stage failure rates. The cost of failed clinical trials is high, and the burden placed on ways to reduce the continuously high failure rate provides impetus for drug discovery technologies market.
Select Competitors (Total 129 Featured) -

• Affymetrix Inc.

• Agilent Technologies, Inc.

• Curia Global, Inc.

• Astrazeneca plc

• Bayer Healthcare AG

• Bio-Rad Laboratories Inc.

• Charles River Laboratories International Inc.

• Evotec Ag

• GYROS PROTEIN TECHNOLOGIES AB

• Illumina, Inc.

• Luminex Corporation

• Merck KGaA

• Molecular Discovery Ltd.

• Novartis AG

• Thermo Fisher Scientific Inc.

Read the full report: https://www.reportlinker.com/p05817664/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Drug Discovery Technologies - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
A Prelude to Drug Discovery Technologies
Impact of Pandemic on Drug Discovery Market
Global Market Analysis and Prospects
Global Drug Discovery Technologies Market Set to Witness Rapid
Growth
Regional Market Analysis
Market Analysis based on Application
Market Analysis based on End-User
Competition
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Late-Stage Drug Failures Drives Demand for Drug Discovery
Technolgies
Average Cost of Drug Development (In Us$ Billion) in the US
Since 1980s
Factors Leading to Failure of Drugs in Phase III Clinical
Trials: Percentage Breakdown of Number of Cases for Efficacy,
Pharmacokinetics, Toxicity and Others
Cell-based Assays Play a Critical Role in Drug Discovery
Table 1: Cell-based Assays Market by Application (2020):
Percentage Share Breakdown of Value Sales for Drug Discovery,
ADME Testing, and Basic Research
Major Types of Cell-Based HTS Assays for Drug Screening
Table 2: Global Cell-based Assays Market by Segment (2020):
Percentage Share Breakdown of Value Sales for Consumables,
Instruments, Software, and Services
High-Content Screening (HCS) - An Expanding Technology in Cell
-Based Assays
High Content Screening - Key Application Areas
Technology Advances in Drug Discovery Processes
Increased Demand of Biochips in Drug Discovery to Drive Market
Growth
Increased Demand for Personalized Medicine to Drive Drug
Discovery Technologies Market
Global Personalized Medicine Market: Revenues in US$ Million
for the Years 2019, 2021, 2023 and 2025
Proteomics and Genomics Drive Opportunities for Drug Discovery
Technologies
Proteomics Profiling to Expedite Drug Discovery
Other Applications of Proteomics in Drug Discovery
New Proteomics Technique to Aid Drug Screening & Biomarker
Discovery
Proteomic Approaches Gain Prominence in Cancer Drug Discovery
Proteomics Technologies Used in Cancer Drug Discovery and
Development
Role of Proteomics in Oncology Biomarker Discovery
Gaining Insights into COVID-19 & Drug Discovery with Proteomics
Bioinformatics Tools along with Proteomics Accelerate the
Process of Pathway Prediction
Using AI in Drug Discovery: The Latest Market Research
High-throughput Screening (HTS) - A Key Drug Discovery Technology
HTS: Making Use of a Smarter Approach to Hit Discovery
Emerging Technologies in Drug Discovery and Development
Targeted Drug Development and Discovery
Significance of Advanced Clinical Sequencing for Drug Developers
Metabolomics: An Emerging Trend in Drug Discovery
Impact of ADME-Tox Screening on New Drug Discovery
Phase-I Clinical Trial Failures Before and After the Advent of
Preclinical ADME/Pharmacokinetics
Pharma Industry Renews Focus on Cost Optimization
Global Pharmaceutical R&D Spending (US$ Billion) for the Years
2011 through 2020
China and India: Hot Spots for R&D Investment
World R&D Market by Geographic Region (2020): Percentage
Breakdown of R&D Spending for Asia, Europe, Middle East &
Africa, North America and South America
Omics Technology to Witness Rapid Growth
Adoption of Omics-based Technologies
Increasing Demand for 3D Cell Culture in Drug Discovery

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Drug Discovery Technologies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 3: World 15-Year Perspective for Drug Discovery
Technologies by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2012, 2021 &
2027

Table 4: World Recent Past, Current & Future Analysis for Small
Molecule Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Small Molecule Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 6: World 15-Year Perspective for Small Molecule Drugs by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Biologics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2020
through 2027 and % CAGR

Table 8: World Historic Review for Biologics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Million for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Biologics by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for High
Throughput Screening by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for High Throughput Screening
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 12: World 15-Year Perspective for High Throughput
Screening by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Biochips by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2020
through 2027 and % CAGR

Table 14: World Historic Review for Biochips by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Million for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Biochips by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Bioinformatics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Bioinformatics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 18: World 15-Year Perspective for Bioinformatics by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Pharmacogenomics & Pharmacogenetics by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Pharmacogenomics &
Pharmacogenetics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Pharmacogenomics &
Pharmacogenetics by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Nanotechnology by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Nanotechnology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 24: World 15-Year Perspective for Nanotechnology by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Other Technologies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Other Technologies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 27: World 15-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for
Research Institutes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Research Institutes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 30: World 15-Year Perspective for Research Institutes by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 31: World Recent Past, Current & Future Analysis for
Pharmaceutical Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Pharmaceutical Companies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 33: World 15-Year Perspective for Pharmaceutical
Companies by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2021 & 2027

Table 34: World Recent Past, Current & Future Analysis for
Biotechnology Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Biotechnology Companies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 36: World 15-Year Perspective for Biotechnology Companies
by Geographic Region - Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 37: World Recent Past, Current & Future Analysis for
Other End-Uses by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR

Table 39: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Drug Discovery Technologies Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2022
(E)
Table 40: USA Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Type - Small Molecule Drugs and
Biologics - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Drug Discovery Technologies
by Type - Small Molecule Drugs and Biologics Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Drug Discovery
Technologies by Type - Percentage Breakdown of Value Revenues
for Small Molecule Drugs and Biologics for the Years 2012, 2021 &
2027

Table 43: USA Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Technology - High Throughput
Screening, Biochips, Bioinformatics, Pharmacogenomics &
Pharmacogenetics, Nanotechnology and Other Technologies -
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Drug Discovery Technologies
by Technology - High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Drug Discovery
Technologies by Technology - Percentage Breakdown of Value
Revenues for High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies for the Years 2012, 2021 &
2027

Table 46: USA Recent Past, Current & Future Analysis for Drug
Discovery Technologies by End-Use - Research Institutes,
Pharmaceutical Companies, Biotechnology Companies and Other
End-Uses - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Drug Discovery Technologies
by End-Use - Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 48: USA 15-Year Perspective for Drug Discovery
Technologies by End-Use - Percentage Breakdown of Value
Revenues for Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses for the Years 2012,
2021 & 2027

CANADA
Table 49: Canada Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Type - Small Molecule Drugs and
Biologics - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Drug Discovery
Technologies by Type - Small Molecule Drugs and Biologics
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Drug Discovery
Technologies by Type - Percentage Breakdown of Value Revenues
for Small Molecule Drugs and Biologics for the Years 2012, 2021 &
2027

Table 52: Canada Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Technology - High Throughput
Screening, Biochips, Bioinformatics, Pharmacogenomics &
Pharmacogenetics, Nanotechnology and Other Technologies -
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Drug Discovery
Technologies by Technology - High Throughput Screening,
Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Drug Discovery
Technologies by Technology - Percentage Breakdown of Value
Revenues for High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies for the Years 2012, 2021 &
2027

Table 55: Canada Recent Past, Current & Future Analysis for
Drug Discovery Technologies by End-Use - Research Institutes,
Pharmaceutical Companies, Biotechnology Companies and Other
End-Uses - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for Drug Discovery
Technologies by End-Use - Research Institutes, Pharmaceutical
Companies, Biotechnology Companies and Other End-Uses Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Drug Discovery
Technologies by End-Use - Percentage Breakdown of Value
Revenues for Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses for the Years 2012,
2021 & 2027

JAPAN
Drug Discovery Technologies Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 58: Japan Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Type - Small Molecule Drugs and
Biologics - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Drug Discovery Technologies
by Type - Small Molecule Drugs and Biologics Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Drug Discovery
Technologies by Type - Percentage Breakdown of Value Revenues
for Small Molecule Drugs and Biologics for the Years 2012, 2021 &
2027

Table 61: Japan Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Technology - High Throughput
Screening, Biochips, Bioinformatics, Pharmacogenomics &
Pharmacogenetics, Nanotechnology and Other Technologies -
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Drug Discovery Technologies
by Technology - High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Drug Discovery
Technologies by Technology - Percentage Breakdown of Value
Revenues for High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies for the Years 2012, 2021 &
2027

Table 64: Japan Recent Past, Current & Future Analysis for Drug
Discovery Technologies by End-Use - Research Institutes,
Pharmaceutical Companies, Biotechnology Companies and Other
End-Uses - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Drug Discovery Technologies
by End-Use - Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Drug Discovery
Technologies by End-Use - Percentage Breakdown of Value
Revenues for Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses for the Years 2012,
2021 & 2027

CHINA
Drug Discovery Technologies Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2022 (E)
Table 67: China Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Type - Small Molecule Drugs and
Biologics - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Drug Discovery Technologies
by Type - Small Molecule Drugs and Biologics Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Drug Discovery
Technologies by Type - Percentage Breakdown of Value Revenues
for Small Molecule Drugs and Biologics for the Years 2012, 2021 &
2027

Table 70: China Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Technology - High Throughput
Screening, Biochips, Bioinformatics, Pharmacogenomics &
Pharmacogenetics, Nanotechnology and Other Technologies -
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Drug Discovery Technologies
by Technology - High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR

Table 72: China 15-Year Perspective for Drug Discovery
Technologies by Technology - Percentage Breakdown of Value
Revenues for High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies for the Years 2012, 2021 &
2027

Table 73: China Recent Past, Current & Future Analysis for Drug
Discovery Technologies by End-Use - Research Institutes,
Pharmaceutical Companies, Biotechnology Companies and Other
End-Uses - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Drug Discovery Technologies
by End-Use - Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Drug Discovery
Technologies by End-Use - Percentage Breakdown of Value
Revenues for Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses for the Years 2012,
2021 & 2027

EUROPE
Drug Discovery Technologies Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 76: Europe Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2020
through 2027 and % CAGR

Table 77: Europe Historic Review for Drug Discovery
Technologies by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Drug Discovery
Technologies by Geographic Region - Percentage Breakdown of
Value Revenues for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2012, 2021 & 2027

Table 79: Europe Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Type - Small Molecule Drugs and
Biologics - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Drug Discovery
Technologies by Type - Small Molecule Drugs and Biologics
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Drug Discovery
Technologies by Type - Percentage Breakdown of Value Revenues
for Small Molecule Drugs and Biologics for the Years 2012, 2021 &
2027

Table 82: Europe Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Technology - High Throughput
Screening, Biochips, Bioinformatics, Pharmacogenomics &
Pharmacogenetics, Nanotechnology and Other Technologies -
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Drug Discovery
Technologies by Technology - High Throughput Screening,
Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Drug Discovery
Technologies by Technology - Percentage Breakdown of Value
Revenues for High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies for the Years 2012, 2021 &
2027

Table 85: Europe Recent Past, Current & Future Analysis for
Drug Discovery Technologies by End-Use - Research Institutes,
Pharmaceutical Companies, Biotechnology Companies and Other
End-Uses - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Drug Discovery
Technologies by End-Use - Research Institutes, Pharmaceutical
Companies, Biotechnology Companies and Other End-Uses Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Drug Discovery
Technologies by End-Use - Percentage Breakdown of Value
Revenues for Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses for the Years 2012,
2021 & 2027

FRANCE
Drug Discovery Technologies Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2022 (E)
Table 88: France Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Type - Small Molecule Drugs and
Biologics - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Drug Discovery
Technologies by Type - Small Molecule Drugs and Biologics
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Drug Discovery
Technologies by Type - Percentage Breakdown of Value Revenues
for Small Molecule Drugs and Biologics for the Years 2012, 2021 &
2027

Table 91: France Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Technology - High Throughput
Screening, Biochips, Bioinformatics, Pharmacogenomics &
Pharmacogenetics, Nanotechnology and Other Technologies -
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: France Historic Review for Drug Discovery
Technologies by Technology - High Throughput Screening,
Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR

Table 93: France 15-Year Perspective for Drug Discovery
Technologies by Technology - Percentage Breakdown of Value
Revenues for High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies for the Years 2012, 2021 &
2027

Table 94: France Recent Past, Current & Future Analysis for
Drug Discovery Technologies by End-Use - Research Institutes,
Pharmaceutical Companies, Biotechnology Companies and Other
End-Uses - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 95: France Historic Review for Drug Discovery
Technologies by End-Use - Research Institutes, Pharmaceutical
Companies, Biotechnology Companies and Other End-Uses Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 96: France 15-Year Perspective for Drug Discovery
Technologies by End-Use - Percentage Breakdown of Value
Revenues for Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses for the Years 2012,
2021 & 2027

GERMANY
Drug Discovery Technologies Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2022 (E)
Table 97: Germany Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Type - Small Molecule Drugs and
Biologics - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 98: Germany Historic Review for Drug Discovery
Technologies by Type - Small Molecule Drugs and Biologics
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Drug Discovery
Technologies by Type - Percentage Breakdown of Value Revenues
for Small Molecule Drugs and Biologics for the Years 2012, 2021 &
2027

Table 100: Germany Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Technology - High Throughput
Screening, Biochips, Bioinformatics, Pharmacogenomics &
Pharmacogenetics, Nanotechnology and Other Technologies -
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 101: Germany Historic Review for Drug Discovery
Technologies by Technology - High Throughput Screening,
Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies Markets - Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR

Table 102: Germany 15-Year Perspective for Drug Discovery
Technologies by Technology - Percentage Breakdown of Value
Revenues for High Throughput Screening, Biochips,
Bioinformatics, Pharmacogenomics & Pharmacogenetics,
Nanotechnology and Other Technologies for the Years 2012, 2021 &
2027

Table 103: Germany Recent Past, Current & Future Analysis for
Drug Discovery Technologies by End-Use - Research Institutes,
Pharmaceutical Companies, Biotechnology Companies and Other
End-Uses - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 104: Germany Historic Review for Drug Discovery
Technologies by End-Use - Research Institutes, Pharmaceutical
Companies, Biotechnology Companies and Other End-Uses Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR

Table 105: Germany 15-Year Perspective for Drug Discovery
Technologies by End-Use - Percentage Breakdown of Value
Revenues for Research Institutes, Pharmaceutical Companies,
Biotechnology Companies and Other End-Uses for the Years 2012,
2021 & 2027

ITALY
Table 106: Italy Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Type - Small Molecule Drugs and
Biologics - Independent Analysis of Annual Revenues in US$
Million for the Years 2020 through 2027 and % CAGR

Table 107: Italy Historic Review for Drug Discovery

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05817664/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001